High levels of c-Met is associated with poor prognosis in glioblastoma

In Vivo c-Met Pathway Inhibition Depletes Human Glioma Xenografts of Tumor-Propagating Stem-Like Cells

(2014) Prakash Rath et al.   Translational Oncology

High-Throughput Flow Cytometry Screening Reveals a Role for Junctional Adhesion Molecule A as a Cancer Stem Cell Maintenance Factor

(2014) Justin D. Lathia et al.   Cell Reports

The immunohistochemical expression of c-Met is an independent predictor of survival in patients with glioblastoma multiforme

(2013) O. F. Olmez et al.   Clinical & Translational Oncology

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

(2013) David R. Spigel et al.   JOURNAL OF CLINICAL ONCOLOGY

A population-based study of low-grade gliomas and mutated isocitrate dehydrogenase 1 (IDH1)

(2013) Rikke H. Dahlrot et al.   JOURNAL OF NEURO-ONCOLOGY

Prognostic value of Musashi-1 in gliomas

(2013) Rikke H. Dahlrot et al.   JOURNAL OF NEURO-ONCOLOGY

Glioma Spheroids Obtained via Ultrasonic Aspiration Are Viable and Express Stem Cell Markers

(2013) Stine Skov Jensen et al.   NEUROSURGERY

An Orally Bioavailable c-Met Kinase Inhibitor Potently Inhibits Brain Tumor Malignancy and Growth

(2012) Fadila Guessous et al.   Anti-Cancer Agents in Medicinal Chemistry

METGain in Diffuse Astrocytomas is Associated with Poorer Outcome

(2012) Daniela Pierscianek et al.   BRAIN PATHOLOGY

MET Signaling Regulates Glioblastoma Stem Cells

(2012) K. M. Joo et al.   CANCER RESEARCH

Prospective, high-throughput molecular profiling of human gliomas

(2012) Andrew S. Chi et al.   JOURNAL OF NEURO-ONCOLOGY

MiR-21 expression in the tumor cell compartment holds unfavorable prognostic value in gliomas

(2012) Simon Kjær Hermansen et al.   JOURNAL OF NEURO-ONCOLOGY

Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies

(2011) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Rapid Radiographic and Clinical Improvement After Treatment of a MET-Amplified Recurrent Glioblastoma With a Mesenchymal-Epithelial Transition Inhibitor

(2011) Andrew S. Chi et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma

(2011) P. Y. Wen et al.   NEURO-ONCOLOGY

Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma

(2011) Q. Xie et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype

(2011) Y. Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

An overview of the c-MET signaling pathway

(2011) Shawna Leslie Organ et al.   Therapeutic Advances in Medical Oncology

c-Met expression is associated with time to recurrence in patients with glioblastoma multiforme

(2010) Wei Liu et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Hypoxia-Inducible Factors Regulate Tumorigenic Capacity of Glioma Stem Cells

(2009) Zhizhong Li et al.   CANCER CELL

Prognostic significance of c-Met expression in glioblastomas

(2008) Doo-Sik Kong et al.   CANCER

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE

Malignant Gliomas in Adults

(2008) Patrick Y. Wen et al.   NEW ENGLAND JOURNAL OF MEDICINE